




PCT/EP 03 / 07603

|                   |   |
|-------------------|---|
| REQU 19 AOUT 2003 | <br>INVESTOR IN PEOPLE |
| OMPI PCT          |   |

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ


**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

16 APR 2003

The  
**Patent  
Office**

1 / 77

**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

**The Patent Office**

Cardiff Road  
Newport  
Gwent NP10 8QQ

|    |   |   |  |  |
|----|---|---|--|--|
| 1. | Your reference  | G-32500P1/BCK 9919  |  |  |
| 2. | Patent application number<br>(The Patent Office will fill in this part)   | 0216418.4   |  | 15 JUL 2002<br>16JUL02 E733520-1 000524<br>P01/7700 0.00-0216418.4 |
| 3. | Full name, address and postcode of the<br>or of each applicant<br>(underline all surnames)  | BIOCHEMIE GESELLSCHAFT MBH<br>A-6250 KUNDL/TIROL<br>AUSTRIA<br><br>389911001                                    |  |  |
|    | Patent ADP number (if you know it)  |   |  |  |
|    | If the applicant is a corporate body,<br>give the country/state of its<br>incorporation   | AUSTRIA   |  |  |
| 4. | Title of invention  | Organic compound.   |  |  |
| 5. | Name of your agent (If you have one)  |   |  |  |
|    | "Address for service" in the United<br>Kingdom to which all correspondence<br>should be sent<br>(including the postcode)  | B.A. YORKE & CO.<br>CHARTERED PATENT AGENTS<br>COOMB HOUSE, 7 ST. JOHN'S ROAD<br>ISLEWORTH<br>MIDDLESEX TW7 6NH |  |  |
|    | Patents ADP number (if you know it)   | 1800001 ✓   |  |  |
| 6. | If you are declaring priority from one<br>or more earlier patent applications,<br>give<br>the country and the date of filing of<br>the or of each of these earlier<br>applications and (if you know it) the or<br>each application number | Country   | Priority application<br>number<br>(if you know it) | Date of filing<br>(day/month/year<br>)                             |
| 7. | If this application is divided or<br>otherwise derived from an earlier UK<br>application, give the number and the<br>filing date of the earlier application   | Number of earlier<br>application  | Date of filing<br>(day/month/year)                 |  |
| 8. | Is a statement of inventorship and of<br>right to grant of a patent required in<br>support of this request? (Answer 'Yes' if:   | Yes   |  |  |
|    | a) any applicant named in part 3 is not an<br>inventor, or  |   |  |  |
|    | b) there is an inventor who is not named as<br>an applicant, or   |   |  |  |
|    | c) any named applicant is a corporate<br>body.  |   |  |  |
|    | (see note (d))  |   |  |  |

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 7

Claim(s) 1

Abstract 1

Drawing(s) *fm*

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*) ONE

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

11. I/We request the grant of a patent on the basis of this application

Signature

Date

*B.A. Yorke & Co.*

B.A. Yorke & Co.

15 July 2002

12. Name and daytime telephone number of person to contact in the United Kingdom  
Mrs. E. Cheetham  
020 8560 5847

### Warning

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*



indanyl, phthalidyl, alkoxycarbonyloxy and ester moieties which form with the  $\text{COO}^-$  group a physiologically hydrolysable and acceptable ester, e.g. such known to be hydrolysable ester groups in the field of cephalosporins. Such esters may be administered preferably orally. Parenteral administration may be indicated if the ester *per se* is an active compound or, if hydrolysis occurs in the blood.

In this specification unless otherwise indicated the compound of formula I embraces the compound in any form, for example in the form of a salt and in free base form. The present invention thus includes a compound in free base form or, e.g. where such forms exist, in the form of a salt, for example in the form of an acid addition salt, inner salt, quaternary salt and/or in the form of a solvate, for example in the form of a hydrate. A salt may be a pharmaceutically acceptable salt of a compound of formula I such as a metal salt or an amine salt. Metal salts include for example sodium, potassium, calcium, barium, zinc, aluminum salts, preferably sodium or potassium salts. Amine salts include for example trialkylamine, procaine, dibenzylamine and benzylamine salts. A free form of a compound of formula I may be converted into a salt/solvate form and *vice versa*.

In a further aspect the present invention provides a compound of formula I in free form and in the form of a salt, for example an acid addition salt or a metal salt; and a compound of formula I, e.g. in free form or in the form of a salt, in the form of a solvate.

The present invention includes a compound of formula I in any isomeric form in which it may exist. E.g. the configuration may be syn [(Z)] and anti [(E)] and is preferably syn [(Z)]. E.g. geometric isomers may be obtained, e.g. during a production process of a compound of formula I, e.g. due to the presence of a  $-\text{CH}=\text{CN}-$  double bond. E.g. a chiral carbon atom may be introduced, e.g. during a production process of a compound of formula I and corresponding stereoisomeric forms of a compound of formula I may be obtained, e.g. a mixture of the individual stereoisomers, e.g. a racemate, or pure isostereoisomeric forms. Mixtures of isomers may be separated.

The present invention includes a compound of formula I in any tautomeric form.

The compounds mentioned herein may be prepared as appropriate, e.g. according to a method as conventional or as disclosed herein.

In another aspect the present invention provides a process for the production of a compound of formula I by reaction of 4-amino-1((1-methylhydrazino)iminomethyl) with N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto(2,1-b)furo(3,4-d)(1,3)-thiazin-6-yl)-2-(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-(fluoromethoxyimino) acetic acid amide.

5

If desired, reactive groups in starting materials may be protected with protecting groups, which may be, or, which are split off under the reaction conditions, or after termination of the reaction. A compound of formula I wherein R is hydrogen may be converted into a compound of formula I wherein R is an carboxylic acid ester group and vice versa. A  
10 compound of formula I may be isolated from the reaction mixture as appropriate, e.g. according to a method as conventional.

15

The compounds of formula I including salt/solvate, hereinafter designated as "active compound(s) of the invention" exhibits pharmacological activity, e.g. beside low toxicity and are therefore useful as pharmaceuticals. In particular, the active compounds of the invention show antimicrobial, e.g. antibacterial, activity against e.g. gram negative and gram positive bacteria, e.g. gram positive bacteria such as Escherichia, e.g. Escherichia coli; Enterobacter, e.g. Enterobacter cloacae; Enterococcus, e.g. Enterococcus faecalis; Klebsiella, e.g. Klebsiella pneumoniae; Streptococcus, e.g. Streptococcus pneumoniae; Staphylococcus, e.g. Staphylococcus aureus; and Pseudomonas, e.g. Pseudomonas aeruginosa, in vitro in the  
20 Agar Dilution Test according to National Committee for Clinical Laboratory Standards (NCCLS) 1993, Document M7-A3Vol.13, No. 25: "Methods for dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Third Edition, Approved Standard". The active compounds show an MIC ( $\mu\text{g/ml}$ ) in the Agar Dilution Test from about  $<0.0125$  to  
25 ca.  $>25.6$ . The active compounds of the invention show an surprising overall activity spectrum.

30

The active compounds of the present invention in the form of a salt exhibit the same order of activity as the active compounds of the present invention in free form; optionally in the form of a solvate.

In another aspect the present invention provides an active compound for use as a pharmaceutical, preferably as an antimicrobial agent, such as an antibiotic.

In a further aspect the present invention provides an active compound of the present invention for use in the preparation of a medicament for the treatment of microbial diseases, for example of diseases caused by bacterias selected from *Escherichia*, *Enterobacter*, *Enterococcus*, *Klebsiella*, *Streptococcus*, *Staphylococcus* and *Pseudomonas*.

5

In a further aspect the present invention provides a method of treatment of microbial diseases which comprises administering to a subject in need of such treatment an effective amount of an active compound of the present invention.

For this indication, the appropriate dosage will, of course, vary depending upon, for example, the compound of formula I employed, the host, the mode of administration and the nature and severity of the conditions being treated. However, in general, for satisfactory results in larger mammals, for example humans, an indicated daily dosage is in the range from about 0.05 to 5 g, for example 0.1 to about 2.5 g, of an active compound of the invention conveniently administered, for example, in divided doses up to four times a day.

15 An active compound of the invention may be administered by any conventional route, for example orally, e.g. in form of tablets or capsules, or parenterally in the form of injectable solutions or suspensions, e.g. in analogous manner to ceftazidime.

20 Because of the compounds activity against various e.g. bacterial strains, compounds of formula I are indicated for the treatment of microbial diseases, e.g. bacterial diseases. The compounds of the invention may be administered to larger mammals, for example humans, by similar modes of administration at similar dosages than conventionally employed with ceftazidime.

25 The compound of formula I may be administered in pharmaceutically acceptable salt form, e.g. acid addition salt form or base addition salt form or in the corresponding free forms, optionally in solvate form. Such salts exhibit the same order of activity as the free forms.

30 The present invention also provides pharmaceutical compositions comprising an active compound of the present invention in association with at least one pharmaceutical carrier or diluent. Such compositions may be manufactured accordingly, e.g. analogously to a method as conventional.

The present invention provides in further aspects

- an active compound of the present invention for use as a pharmaceutical in the treatment of microbial diseases caused by bacterias selected from Escherichia, Enterobacter, Enterococcus, Klebsiella, Streptococcus, Staphylococcus and Pseudomonas;
- 5   - the use of an active compound of the present invention or the use of a pharmaceutical composition comprising an active compound of the present invention as a pharmaceutical and
- a method of treatment of microbial diseases which comprises administering to a subject in need of such treatment an effective amount of an active compound of the present invention.
- 10   Treatment includes disease treatment as well as prophylactic treatment.



**Example 1:****a) Benzylidene derivative of trans-4-amino-1((1-methylhydrazino)iminomethyl)-cyclohexane monohydrochloride**

35 g of the benzylidene derivative of S-methyl-2-methyl-isothiosemicarbazide hydrochloride and 32.79 g trans-1,4-diaminocyclohexane in 300 ml MeOH are refluxed and the reaction mixture is stirred at room temperature. A precipitate is formed, is filtered off, solvent from the filtrate obtained is removed and the residue obtained is treated with HCl. A precipitate is formed, is filtered off, washed and discarded. The volume of the filtrate obtained is brought to about 150 ml and the resulting suspension is kept over night at 4°C. A precipitate formed is filtered off, washed with water and acetonitrile, dried and recrystallized from water.

25.48 g of benzylidene derivative of trans-4-amino-1((1-methylhydrazino)iminomethyl)-cyclohexane in the form of a monohydrochloride are obtained as a solid.

**b) trans-4-amino-1((1-methylhydrazino)iminomethyl)cyclohexane dihydrochloride**

Benzaldehyde is distilled off by steam distillation from a mixture of 24.74 g benzylidene derivative of trans-4-amino-1((1-methylhydrazino)iminomethyl)cyclohexane in the form of a monohydrochloride and 79.9 ml 2 M HCl and solvent from the remaining mixture is evaporated off. 15.62 g of trans-4-amino-1((1-methylhydrazino)iminomethyl)-cyclohexane in the form of a dihydrochloride are obtained as a solid.

**Example 2****a) 3-{(E)[[1-trans-(4-amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl}-7-{2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-fluoromethoxyimino]-acetylamino}-cephem-4-carboxylic acid trihydrochloride**

To a mixture of 2 g trans-4-amino-1((1-methylhydrazino)iminomethyl)cyclohexane in the form of a dihydrochloride in 3.4 ml 2 M HCl and 6.1 ml dimethylacetamide, 2.78 g of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto(2,1-b)furo(3,4-d)(1,3)-thiazin-6-yl)-2-(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-(fluoromethoxyimino) acetic acid amide are added, the suspension obtained is stirred at room temperature and poured into 150 ml of acetonitrile under stirring. A precipitate forms, is filtrated off, washed and dried. 4.69 g of crude 3-{(E)[[1-trans-(4-amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl}-7-{2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-fluoromethoxyimino]-acetylamino}-cephem-4-carboxylic acid trihydrochloride are obtained in the form of a powder.

**b) 3-{(E)[[1-trans-(4-amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl}-7-{2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-fluoromethoxyimino]-acetylamino}-cephem-4-carboxylic acid monohydrochloride**

10 g of crude 3-{(E)[[1-trans-(4-amino-cyclohexylamino)-iminomethyl]-methylhydrazono]-methyl}-7-{2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-fluoromethoxyimino]-acetylamino}-cephem-4-carboxylic acid in the form of a trihydrochloride are dissolved in 42 ml water and the dissolution obtained is subjected to chromatography (LiChroprep RP-18<sup>R</sup>, Merck, grain size 40-63  $\mu$ m; eluens: 95/5 water/acetonitrile). Fractions containing the desired 3-{(E)[[1-trans-(4-amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl}-7-{2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-fluoromethoxyimino]-acetylamino}-cephem-4-carboxylic acid monohydrochloride (HPLC determination) are combined and lyophilized.


5.28 g of 3-{(E)[[1-trans-(4-amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl}-7-{2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-fluoromethoxyimino]-acetylamino}-cephem-4-carboxylic acid in the form of a monohydrochloride are obtained as a lyophilizate.

**<sup>1</sup>H-NMR-Spectra (200 MHz, DMSO-d<sub>6</sub>):**

1.30 – 1.70, m, 4H, CCH<sub>2</sub>; 1.80 – 2.10, m, 4H, CCH<sub>2</sub>; 2.88 – 3.10, m, 1H, NCH; 3.32, s, 3H, NCH<sub>3</sub>; 3.42 – 3.70, m, 2H, 1H from SCH<sub>2</sub> and 1H from NCH; 4.25, part of the AB-quartet, J=18 Hz, 1H, SCH<sub>2</sub>; 5.28, d, J=5 Hz, 1H,  $\beta$ -lactam; 5.79, d, J=55 Hz, 2H, CH<sub>2</sub>F; 5.75, dd, J=5 Hz and 8 Hz, 1H,  $\beta$ -lactam; 8.10, s, 1H, CH=N; 9.84, d, J=8 Hz, 1H, NH

## Claims:

1. A compound of formula



5

wherein

R is H or an ester moiety.

10

2. A compound according to claim 1 in the form of a salt or in the form of a solvate or in the form of a salt and a solvate.

3. A pharmaceutical composition comprising a compound according to any one of claims 1 to 2 in association with at least one pharmaceutical carrier or diluent.

15

4. Use of a compound according to any one of claims 1 to 2 as a pharmaceutical.


5. Use according to claim 4 in the treatment of microbial diseases.

20

6. A method of treatment of microbial diseases which comprises administering to a subject in need of such treatment an effective amount of a compound according to any one of claims 1 to 2 or a pharmaceutical composition according to claim 3.

### Abstract:

A compound of formula



wherein

**R is H or an ester moiety, useful as a pharmaceutical.**

IL/12-July-2002